Platinum Resistance: The Role of DNA Repair Pathways

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

2005 • 6,083 citations

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1999 • 1,865 citations

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

2006 • 1,691 citations

Hallmarks of 'BRCAness' in sporadic cancers

2004 • 1,586 citations

Molecular mechanisms of resistance and toxicity associated with platinating agents

2006 • 1,477 citations

DNA MISMATCH REPAIR

2005 • 1,296 citations

BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures

2000 • 1,236 citations

Ovarian cancer: strategies for overcoming resistance to chemotherapy

2003 • 1,127 citations

Testicular Germ-Cell Cancer

1997 • 895 citations

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update

1998 • 738 citations

Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer

2003 • 680 citations

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

2002 • 667 citations

Oxaliplatin: A review of preclinical and clinical studies

1998 • 611 citations

ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

2001 • 608 citations

The role of DNA mismatch repair in platinum drug resistance.

1996 • 607 citations

Breast and Ovarian Cancer

2003 • 605 citations

Mechanisms of resistance to cisplatin and carboplatin

2007 • 598 citations

Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

2003 • 541 citations

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

1998 • 512 citations

Loss of DNA mismatch repair in acquired resistance to cisplatin.

1996 • 505 citations

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

2000 • 487 citations

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

2007 • 452 citations

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

2003 • 383 citations

Cellular and molecular determinants of cisplatin resistance

1998 • 377 citations

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

1999 • 350 citations

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

2003 • 313 citations

ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients

1992 • 302 citations

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours

1999 • 295 citations

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells

2000 • 265 citations

Epigenetic lesions causing genetic lesions in human cancer

2000 • 256 citations

The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

2004 • 249 citations

Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines

2004 • 207 citations

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

2005 • 188 citations

Distinct methylation pattern and microsatellite instability in sporadic gastric cancer

1999 • 173 citations

Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma

2004 • 145 citations

Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies

2003 • 122 citations

Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma

2003 • 111 citations

Structure and function of the components of the human DNA mismatch repair system

2006 • 110 citations

P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.

2001 • 103 citations

Molecular Mechanisms Underlying Hereditary Nonpolyposis Colorectal Carcinoma

1996 • 100 citations

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

2006 • 88 citations

Mismatch repair and response to DNA-damaging antitumour therapies

2003 • 81 citations

Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin

1998 • 80 citations

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

2006 • 79 citations

Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.

2003 • 62 citations

Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance

2005 • 60 citations

A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer

2001 • 58 citations

Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients

2006 • 35 citations